-+ 0.00%
-+ 0.00%
-+ 0.00%
Sonic Incytes Medical Announces Multi-Year Partnership With Madrigal Pharma To Advance Assessment And Risk Stratification Of Patients With Or At Risk For MASH
Share
Listen to the news

Partnership aims to help more clinicians assess and risk-stratify patients with or at risk for metabolic dysfunction-associated steatohepatitis (MASH), using point-of-care liver assessment.

Sonic Incytes Medical Corp., developer of the Velacur™ point-of-care liver assessment platform, today announced a multi-year partnership with Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for MASH, to advance the assessment and risk stratification of patients with or at risk for MASH.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending